SCHEMBL29653353

SCHEMBL29653353

Cc1cc(CO)ccc1B(O)O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.45
HSD17B10 Q99714 1/20 0.42
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
LPL P06858 2/20 0.35
LIPG Q9Y5X9 2/20 0.35
SHBG P04278 1/20 0.35
S1PR1 P21453 3/20 0.33
S1PR4 O95977 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
MAOA P21397 1/20 0.33
DYRK1A Q13627 1/20 0.33
RECQL P46063 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6487851 1.00 ENPP2 (0.45) ENPP2HSD17B10ESR1ESR2LPL
SCHEMBL29653364 0.83 ENPP2 (0.45) ENPP2HSD17B10ESR1ESR2LPL
SCHEMBL24456142 0.83 ENPP2 (0.45) ENPP2HSD17B10ESR1ESR2LPL
SCHEMBL13885830 0.83 LPL (0.50) HSD17B10ESR1ESR2LPLLIPG
SCHEMBL24803737 0.81 F11 (0.47) ENPP2ESR1ESR2LPLLIPG
SCHEMBL28466396 0.79 LPL (0.53) ESR1ESR2LPLLIPG
SCHEMBL3784877 0.78 ENPP2 (0.45) ENPP2HSD17B10LPLLIPGSHBG
SCHEMBL16576672 0.78 ESR1 (0.45) HSD17B10ESR1ESR2LPLLIPG
SCHEMBL2295096 0.77 ENPP2 (0.44) ENPP2HSD17B10LPLLIPGCYP4F2
SCHEMBL29730087 0.77 ENPP2 (0.44) ENPP2HSD17B10LPLLIPGCYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001886-A1 ENPP1 INHIBITORS I RE VENTURES I LLC (US) 2026-01-01 US disclosed
WO-2025233863-A1 ENPP1 INHIBITORS RE VENTURES I, LLC (US) 2025-11-13 WO disclosed
WO-2022250104-A1 QUINOLONE DERIVATIVE HAVING ANTIMALARIAL ACTIVITY 国立大学法人長崎大学 2022-12-01 WO disclosed
EP-4069696-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-10-12 EP disclosed
WO-2022109492-A1 PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS GOSSAMER BIOSERVICES, INC. (US) 2022-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001886-A1 ENPP1 INHIBITORS I ENPP1, ENPP2, ENPP3 ENPP2 2/4885HSD17B10 1767/4885ESR1 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.